001     128088
005     20240228145533.0
024 7 _ |a 10.1038/bjc.2017.231
|2 doi
024 7 _ |a pmid:28765617
|2 pmid
024 7 _ |a pmc:PMC5572182
|2 pmc
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
024 7 _ |a altmetric:23351418
|2 altmetric
037 _ _ |a DKFZ-2017-04110
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Lophatananon, Artitaya
|b 0
245 _ _ |a Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
260 _ _ |a Edinburgh
|c 2017
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660821245_27718
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Stewart-Brown, Sarah
|b 1
700 1 _ |a Kote-Jarai, Zsofia
|b 2
700 1 _ |a Olama, Ali Amin Al
|b 3
700 1 _ |a Garcia, Sara Benlloch
|b 4
700 1 _ |a Neal, David E
|b 5
700 1 _ |a Hamdy, Freddie C
|b 6
700 1 _ |a Donovan, Jenny L
|b 7
700 1 _ |a Giles, Graham G
|b 8
700 1 _ |a Fitzgerald, Liesel M
|b 9
700 1 _ |a Southey, Melissa C
|b 10
700 1 _ |a Pharoah, Paul
|b 11
700 1 _ |a Pashayan, Nora
|b 12
700 1 _ |a Gronberg, Henrik
|b 13
700 1 _ |a Wiklund, Fredrik
|b 14
700 1 _ |a Aly, Markus
|b 15
700 1 _ |a Stanford, Janet L
|b 16
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 17
|u dkfz
700 1 _ |a Dieffenbach, Aida K
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 19
|u dkfz
700 1 _ |a Park, Jong Y
|b 20
700 1 _ |a Lin, Hui-Yi
|b 21
700 1 _ |a Sellers, Thomas
|b 22
700 1 _ |a Slavov, Chavdar
|b 23
700 1 _ |a Kaneva, Radka
|b 24
700 1 _ |a Mitev, Vanio
|b 25
700 1 _ |a Batra, Jyotsna
|b 26
700 1 _ |a Spurdle, Amanda
|b 27
700 1 _ |a Clements, Judith A
|b 28
700 1 _ |a BioResource, APCB
|b 29
|e Collaboration Author
700 1 _ |a consortium, PRACTICAL
|b 30
|e Collaboration Author
700 1 _ |a Easton, Douglas
|b 31
700 1 _ |a Eeles, Rosalind A
|b 32
700 1 _ |a Muir, Kenneth
|b 33
773 _ _ |a 10.1038/bjc.2017.231
|g Vol. 117, no. 5, p. 734 - 743
|0 PERI:(DE-600)2002452-6
|n 5
|p 734 - 743
|t British journal of cancer
|v 117
|y 2017
|x 1532-1827
909 C O |p VDB
|o oai:inrepo02.dkfz.de:128088
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2015
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
920 1 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)C071-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21